Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BELDEN INC. Director's Dealing 2025

Feb 26, 2025

31053_dirs_2025-02-25_bcb0986a-5bd1-46be-980b-1e6a6ef492af.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BELDEN INC. (BDC)
CIK: 0000913142
Period of Report: 2025-02-21

Reporting Person: Tate Leah (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-02-21 Common Stock F 435 Disposed 22808 Direct
2025-02-24 Common Stock F 241 Disposed 22567 Direct
2025-02-24 Common Stock M 441 $53.79 Acquired 23008 Direct
2025-02-24 Common Stock D 277 $111.09 Disposed 22731 Direct
2025-02-25 Common Stock S 164 $111.76 Disposed 22567 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-02-24 Stock Appreciation Rights $53.79 M 441 Disposed 2032-02-22 Common Stock (441) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 3360 Indirect
Common Stock 1030.1076 Indirect

Footnotes

F1: Shares withheld for tax purposes related to portion of February 21, 2024 restricted stock unit grant that vested on February 21, 2025.

F2: Shares withheld for tax purposes related to February 22, 2022 restricted stock unit grant that vested on February 24, 2025.

F3: Represents the balance of shares of Belden Inc. common stock held in the Belden Retirement Savings Plan as of the date of this filing.

F4: The exercise reported was effected pursuant to a Rule 10b5-1 trading plan adopted by Ms. Tate on November 8, 2024.

F5: This represents the difference between the number of SARs exercised (441) and the number of shares issued as a result of the exercise (164). The number of shares to be issued under a SAR exercise is determined by multiplying the number of SARs being exercised by the difference between the FMV on the date of exercise ($111.09) and the exercise price ($53.79). Additional shares were then withheld to satisfy the Company's tax withholding obligations.

F6: The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by Ms. Tate on November 8, 2024.